Cabaletta Bio (CABA) Interest & Investment Income (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Interest & Investment Income of $1.3 million for Q4 2025, down 31.9% year-over-year from $1.9 million in Q4 2024, and down 26.66% quarter-over-quarter from $1.8 million in Q3 2025.
Analysis
Cabaletta Bio (CABA) Interest & Investment Income (2018 - 2026) Analysis & Trends
Cabaletta Bio's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $1.3 million for Q4 2025.
- In Q4 2025, Interest & Investment Income fell 31.9% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $6.0 million (down 39.84% YoY), while the FY2025 annual figure was $6.0 million, down 39.84% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $1.3 million, down from $1.8 million in the prior quarter.
- The five-year high for Interest & Investment Income was $3.0 million in Q1 2024, with the low at $3000.0 in Q3 2021.
- The 5-year median for Interest & Investment Income is $1.4 million (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2021 and 2022: Interest & Investment Income tumbled 97.56% in 2021, then surged 12100.0% in 2022.
- Cabaletta Bio's Interest & Investment Income stood at $5000.0 in 2021, then soared by 12100.0% to $610000.0 in 2022, then jumped by 270.49% to $2.3 million in 2023, then slipped by 13.85% to $1.9 million in 2024, then sank by 31.9% to $1.3 million in 2025.
- Business Quant data shows CABA's Interest & Investment Income at $1.3 million in Q4 2025, $1.8 million in Q3 2025, and $1.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - | 1.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.68 Mn |
| Mar 31, 2024 | 2.98 Mn |
| Dec 31, 2023 | 2.26 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 610,000.00 |
| Sep 30, 2022 | 351,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 6,000.00 |